Actelion awarded the Prix Hermès de l'Innovation
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion awarded the Prix Hermès de l'Innovation
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 31 March 2011 - Actelion Ltd (SIX: ATLN) today
announced that the company will receive this year's Prix Hermès de l'Innovation
in the category "amélioration de la condition humaine" (improvement in the
conditions of human life).
The European Institute for Creative Strategies and Innovation awards the Prix
Hermès annually to selected institutions and companies in recognition of their
outstanding innovative achievements in different areas of life. It includes a
total of eight different categories. The award ceremony will take place in Paris
on April 19(th).
Actelion receives the Prix Hermès for its extensive innovative research work for
improving the quality of life of patients. In particular, the Prize recognizes
Actelion's commitment to improve treatment of children with rare diseases,
especially in pulmonary arterial hypertension.
Martine Clozel, Chief Scientific Officer of Actelion, said: "We are honored to
be awarded this Prize, which acknowledges the commitment of Actelion to
innovative research for the benefit of patients with rare diseases. In
particular, it recognizes our efforts to help children. With Tracleer, we began
developing a formulation adapted to children with pulmonary arterial
hypertension particularly early in the development".
Marc Giget, founder and scientific director of the European Institute for
Creative Strategies and Innovation, explained that "Actelion is being awarded
the prize in the category "Improvement in the conditions of life" in recognition
of its overall innovative achievements as a leading company in the biotech
sector. Since it was founded, Actelion has remained true to its corporate
philosophy and now markets four medicines with which a great many patients have
been helped."
###
Note for publisher:
The European Institute for Creative Strategies and Innovation is a Paris-based
think-tank dedicated to the research and dissemination of innovative ideas and
strategies in Europe and the rest of the world.
About Pulmonary Arterial Hypertension in Children
Pulmonary arterial hypertension (PAH) is a severe condition in children with an
estimated median survival of 10 months after diagnosis, if left untreated.
Online information on PAH is available at www.pah-info.com. PAH-info.com is part
of an international PAH awareness campaign supported by Actelion Pharmaceuticals
and has been created to provide information to healthcare professionals and
patients.
There is a specifically tailored, age-appropriate pediatric formulation of
Tracleer. It is the only approved pediatric PAH formulation. The pediatric
formulation has been well received by the European PAH community as it becomes
available in more and more countries. It underlines Actelion's commitment to
small patient populations with specific needs.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(®), an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI(®)).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1501999/437251.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1501999]
Unternehmensinformation / Kurzprofil:
Datum: 31.03.2011 - 11:00 Uhr
Sprache: Deutsch
News-ID 53009
Anzahl Zeichen: 5704
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 285 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion awarded the Prix Hermès de l'Innovation"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
